```markdown
---
application_number: NDA 206610
application_type: Complete Response
sponsor:
  name: Mylan Laboratories Limited
  contact_company: Mylan Pharmaceuticals Inc.
  address: 781 Chestnut Ridge Road, Morgantown, WV 26505
contact_person:
  name: Shane Shupe
  title: Director, Regulatory Affairs
product:
  name: Acetaminophen for Injection
  strength: 1 g/vial
submission_dates:
  original_application: 2014-05-05
  complete_response: 2018-12-06
regulations:
  section: 505(b)(2) of the Federal Food, Drug, and Cosmetic Act
not_approved: true
signatory:
  name: Sharon Hertz, MD
  title: Division Director
  division: Division of Anesthesia, Analgesia, and Addiction Products
  office: Office of Drug Evaluation II
review_center: Center for Drug Evaluation and Research
---

## Critical Data

- **Application Number**: NDA 206610  
- **Product Name**: Acetaminophen for Injection  
- **Strength**: 1 g/vial  
- **Sponsor**: Mylan Laboratories Limited (c/o Mylan Pharmaceuticals Inc.)  
- **Contact**: Shane Shupe, Director, Regulatory Affairs  
- **Original Application Date**: May 5, 2014  
- **Complete Response Submission**: December 6, 2018  
- **Application Status**: Not Approved (Complete Response Letter Issued)  
- **Key Regulatory Section**: 505(b)(2) of the Federal Food, Drug, and Cosmetic Act  
- **FDA Reviewer**: Sharon Hertz, MD  
- **Center**: Center for Drug Evaluation and Research (CDER)  

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  

## APPLICATION NUMBER: NDA 206610 - COMPLETE RESPONSE  

### Sponsor  
Mylan Laboratories Limited  
c/o Mylan Pharmaceuticals Inc.  
781 Chestnut Ridge Road  
Morgantown, WV 26505  

### Contact  
Attention: Shane Shupe  
Director, Regulatory Affairs  

---

## INTRODUCTION

Please refer to your new drug application (NDA) dated May 5, 2014, and your amendments, submitted pursuant to Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Acetaminophen for Injection, 1 g/vial.

We acknowledge receipt of your amendments including a complete response dated December 6, 2018.

We have completed our review and determined that we cannot approve this application in its present form. The reasons for this decision and recommendations to address the deficiencies are outlined below.

---

## 1. FACILITY INSPECTIONS  

During a recent inspection of the Mylan Laboratories Limited [Specialty Formulation Facility], our field investigator conveyed deficiencies. Satisfactory resolution of these deficiencies is required for approval.

---

## 2. REGULATORY  

Outstanding deficiencies from May 14, 2019, information request:

- a. Provide updated letters from Mallinckrodt indicating a specific date upon which your application can be approved.  
- b. Provide appropriate patent certification, recertification or statement for U.S. patent 9,399,012.  
- c. Provide patent certification or recertification for the newly proposed condition of use (neonates and infants dosing) in draft labeling.  

---

## 3. PRESCRIBING INFORMATION  

Your proposed Prescribing Information (PI) must conform to 21 CFR 201.56(a) and (d) and 201.57. Refer to:

- Final Rule (Physician Labeling Rule)  
- Final Rule (Pregnancy and Lactation Labeling Rule)  
- Regulations and guidance documents  
- Sample format tool for Highlights and Contents  
- Selected Requirements for Prescribing Information (SRPI)  
- FDA's EPC text phrases for Highlights Indications and Usage  

If you revise labeling, ensure:

- Compliance with SRPI checklist  
- Submission of labeling in SPL format as described at:  
  http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm  

---

## 4. SAFETY UPDATE  

Include safety update in accordance with 21 CFR 314.50(d)(5)(vi)(b):

1. Describe any significant changes/findings in safety profile.  
2. Describe discontinuations/adverse events with updated data:  
    - Present new data using original format  
    - Combine tabulations with original data  
    - Include tables comparing adverse event frequency  
    - Separate tables for non-proposed indications  
3. Retabulate trial discontinuation reasons and identify trends/patterns.  
4. Provide:  
    - Case report forms for deaths and adverse event-related discontinuations  
    - Narrative summaries for serious adverse events  
5. Describe changes in common adverse events incidence.  
6. Provide updated exposure information (e.g., number of subjects, person-time).  
7. Summarize worldwide postmarketing safety experience.  
8. Provide English translations of foreign approved labeling not previously submitted.  

---

## 5. OTHER  

- You must resubmit or take other appropriate action within one year of the date of this letter (21 CFR 314.110).  
- Failure to act may lead to withdrawal of your application under 21 CFR 314.65.  
- Clearly mark your resubmission with "RESUBMISSION" in large, bolded font.  
- Identify your resubmission as a complete response.  
- Partial responses will not initiate a new review cycle.  

You may request a meeting or teleconference per FDA Guidance for Industry [Formal Meetings Between FDA and Sponsors or Applicants of PDUFA Products](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm437431.pdf).

The product cannot be legally marketed until written approval is granted.

---

## SIGNATORIES  

Sharon Hertz, MD  
Division Director  
Division of Anesthesia, Analgesia, and Addiction Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research  

---

## Additional Communications

- Multiple prior Complete Response Letters reference toxicological concerns including:  
  - Unidentified leachables and extractables above toxicological thresholds  
  - Inadequate toxicological risk assessments  

- Required actions:  
  - Identify unknowns exceeding qualification thresholds  
  - Quantify and characterize residual compounds  
  - Provide NOAELs and safety margins based on mg/mÂ²  
  - Revise risk assessment if AET is not met, or justify analytical limitations  

---

## Nonclinical Section (Sample Deficiency)

- As much as unknown material may be present per day, exceeding the toxicological threshold.  
- You must:  
  - Identify extractables and confirm presence in final drug product  
  - Quantify/characterize foreign materials  
  - Submit toxicological risk assessments per FDA requirements  
  - Justify safety assumptions for intravenous use  
  - Include source literature with English translations  

---

## ENCLOSURE  

Labeling (20 pages withheld)
```